• The challenge for Microsoft and Novo Nordisk will be to integrate AI and pharma into a process that will bring cheaper medicines faster with less risk.
• Besides Novo Nordisk, Microsoft entered into a similar partnership with UCB in 2021 as part of the COVID Moon Shot project.
Developing a new drug can take over 12 years and cost $2.6 billion or more. The process is as risky as a trip to Las Vegas as nine out of ten potential new therapies fail to become market-ready products. The cost of a failure is paid for by the company, but ramifications go beyond the bottom line and include loss of life and increased costs to healthcare systems. Even with several high-profile failures, the promise of AI represents a substantial opportunity to transform drug development.
Continue reading “Novo Nordisk and Microsoft Partner to Bring AI to Drug Discovery”